Cargando…
Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model
BACKGROUND: Mounting evidence shows that multi-intervention programmes for hypertension treatment are more effective than an isolated pharmacological strategy. Full economic evaluations of hypertension management programmes are scarce and contain methodological limitations. The aim of the study was...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084155/ https://www.ncbi.nlm.nih.gov/pubmed/21466695 http://dx.doi.org/10.1186/1478-7547-9-4 |
_version_ | 1782202459098185728 |
---|---|
author | Perman, Gastón Rossi, Emiliano Waisman, Gabriel D Agüero, Cristina González, Claudio D Pallordet, Carlos L Figar, Silvana González Bernaldo de Quirós, Fernán Canning, JoAnn Soriano, Enrique R |
author_facet | Perman, Gastón Rossi, Emiliano Waisman, Gabriel D Agüero, Cristina González, Claudio D Pallordet, Carlos L Figar, Silvana González Bernaldo de Quirós, Fernán Canning, JoAnn Soriano, Enrique R |
author_sort | Perman, Gastón |
collection | PubMed |
description | BACKGROUND: Mounting evidence shows that multi-intervention programmes for hypertension treatment are more effective than an isolated pharmacological strategy. Full economic evaluations of hypertension management programmes are scarce and contain methodological limitations. The aim of the study was to evaluate if a hypertension management programme for elderly patients is cost-effective compared to usual care from the perspective of a third-party payer. METHODS: We built a cost-effectiveness model using published evidence of effectiveness of a comprehensive hypertension programme vs. usual care for patients 65 years or older at a community hospital in Buenos Aires, Argentina. We explored incremental cost-effectiveness between groups. The model used a life-time framework adopting a third-party payer's perspective. Incremental cost-effectiveness ratio (ICER) was calculated in International Dollars per life-year gained. We performed a probabilistic sensitivity analysis (PSA) to explore variable uncertainty. RESULTS: The ICER for the base-case of the "Hypertension Programme" versus the "Usual care" approach was 1,124 International Dollars per life-year gained. PSA did not significantly influence results. The programme had a probability of 43% of being dominant (more effective and less costly) and, overall, 95% chance of being cost-effective. DISCUSSION: Results showed that "Hypertension Programme" had high probabilities of being cost-effective under a wide range of scenarios. This is the first sound cost-effectiveness study to assess a comprehensive hypertension programme versus usual care. This study measures hard outcomes and explores robustness through a probabilistic sensitivity analysis. CONCLUSIONS: The comprehensive hypertension programme had high probabilities of being cost-effective versus usual care. This study supports the idea that similar programmes could be the preferred strategy in countries and within health care systems where hypertension treatment for elderly patients is a standard practice. |
format | Text |
id | pubmed-3084155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30841552011-04-29 Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model Perman, Gastón Rossi, Emiliano Waisman, Gabriel D Agüero, Cristina González, Claudio D Pallordet, Carlos L Figar, Silvana González Bernaldo de Quirós, Fernán Canning, JoAnn Soriano, Enrique R Cost Eff Resour Alloc Research BACKGROUND: Mounting evidence shows that multi-intervention programmes for hypertension treatment are more effective than an isolated pharmacological strategy. Full economic evaluations of hypertension management programmes are scarce and contain methodological limitations. The aim of the study was to evaluate if a hypertension management programme for elderly patients is cost-effective compared to usual care from the perspective of a third-party payer. METHODS: We built a cost-effectiveness model using published evidence of effectiveness of a comprehensive hypertension programme vs. usual care for patients 65 years or older at a community hospital in Buenos Aires, Argentina. We explored incremental cost-effectiveness between groups. The model used a life-time framework adopting a third-party payer's perspective. Incremental cost-effectiveness ratio (ICER) was calculated in International Dollars per life-year gained. We performed a probabilistic sensitivity analysis (PSA) to explore variable uncertainty. RESULTS: The ICER for the base-case of the "Hypertension Programme" versus the "Usual care" approach was 1,124 International Dollars per life-year gained. PSA did not significantly influence results. The programme had a probability of 43% of being dominant (more effective and less costly) and, overall, 95% chance of being cost-effective. DISCUSSION: Results showed that "Hypertension Programme" had high probabilities of being cost-effective under a wide range of scenarios. This is the first sound cost-effectiveness study to assess a comprehensive hypertension programme versus usual care. This study measures hard outcomes and explores robustness through a probabilistic sensitivity analysis. CONCLUSIONS: The comprehensive hypertension programme had high probabilities of being cost-effective versus usual care. This study supports the idea that similar programmes could be the preferred strategy in countries and within health care systems where hypertension treatment for elderly patients is a standard practice. BioMed Central 2011-04-05 /pmc/articles/PMC3084155/ /pubmed/21466695 http://dx.doi.org/10.1186/1478-7547-9-4 Text en Copyright ©2011 Perman et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Perman, Gastón Rossi, Emiliano Waisman, Gabriel D Agüero, Cristina González, Claudio D Pallordet, Carlos L Figar, Silvana González Bernaldo de Quirós, Fernán Canning, JoAnn Soriano, Enrique R Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model |
title | Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model |
title_full | Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model |
title_fullStr | Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model |
title_full_unstemmed | Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model |
title_short | Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model |
title_sort | cost-effectiveness of a hypertension management programme in an elderly population: a markov model |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084155/ https://www.ncbi.nlm.nih.gov/pubmed/21466695 http://dx.doi.org/10.1186/1478-7547-9-4 |
work_keys_str_mv | AT permangaston costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel AT rossiemiliano costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel AT waismangabrield costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel AT aguerocristina costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel AT gonzalezclaudiod costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel AT pallordetcarlosl costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel AT figarsilvana costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel AT gonz225lezbernaldodequirosfernan costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel AT canningjoann costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel AT sorianoenriquer costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel |